Novo Nordisk Pharmatech to Attend ESACT
Novo Nordisk Pharmatech has announced it will be attending the 25th European Society for Animal Cell Technology (ESACT) meeting.
The event will be held from 14 May to 17 May in Lausanne, Switzerland. This years’ ESACT programme is designed to provide access to the latest innovation and advances in animal cell technology.
The event will be hosted in the Swiss Tech Convention Centre and Novo Nordisk Pharmatech will be sponsoring the event. The company invites you to visit its stall at booth #65-66.
Novo Nordisk Pharmatech is one of the leading worldwide suppliers of recombinant insulin. Its products are key components in serum-free growth media for mammalian cells and approved by regulatory bodies worldwide, including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its products are also manufactured to current good manufacturing practice (cGMP) standards, guaranteeing:
- Global regulatory compliance
- Consistent high quality
- Extensive regulatory documentation
- Continuous availability
- Secure global supply chain
- High levels of service and support
Novo Nordisk Pharmatech delivers a proven record of product purity, reliability, and consistency. It can even tailor quality products for future therapies.